Indacaterol: A new long-acting β2-agonist in the management of chronic obstructive pulmonary disease

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 7, 2012, Pages 1015-1029

  Steiropoulos, Paschalis ^a   Papanas, Nikolaos ^a   Nena, Evangelia ^a   Bouros, Demosthenes ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Beta agonists; Bronchodilators; Chronic obstructive pulmonary disease; Indacaterol

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; INDACATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

ARTICLE; BLOOD PRESSURE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DISEASE COURSE; DISEASE EXACERBATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EMBASE; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LUNG FUNCTION; MEDLINE; NERVOUSNESS; POTASSIUM BLOOD LEVEL; QT INTERVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT DURATION; TREMOR;

ADRENERGIC BETA-AGONISTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; INDANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RESPIRATORY FUNCTION TESTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84860188145     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.674513     Document Type: Article

References (44)

1. Coultas DB, Mapel D, Gagnon R, Lydick E. The health impact of undiagnosed airflow obstruction in a national sample of United States adults. Am J Respir Crit Care Med 2001;164:372-7 (Pubitemid 32778201)
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global Burden of Disease Study. Lancet 1997;349:1498-04 (Pubitemid 27216360)
3. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available from: http://www.goldcopd.org
4. Michaud CM, Murray CJ, Bloom BR. Burden of disease-implications for future research. JAMA 2001;285:535-9
5. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000;117(Suppl 2):5S-9S (Pubitemid 30111556)
6. Geitona M, Hatzikou M, Steiropoulos P, et al. The cost of COPD exacerbations: a university hospital-based study in Greece. Respir Med 2011;105:402-9
7. Oudijk EJ, Lammers JW, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003;46:5s-13s (Pubitemid 37351732)
8. Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:367-70 (Pubitemid 41699698)
9. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;22:775-89 (Pubitemid 46294610)
10. Mahler DA. The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2002;110:S298-303 (Pubitemid 35471719)
11. Calverley PM. Modern treatment of chronic obstructive pulmonary disease. Eur Respir J 2001;18:60s-6s (Pubitemid 34760610)
12. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301-12 (Pubitemid 37430563)
13. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 2000;355:1931-5 (Pubitemid 30326096)
14. Steiropoulos P, Tzouvelekis A, Bouros D. Formoterol in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008;3:205-15 (Pubitemid 352037881)
15. Lombardi D, Cuenoud B, Kramer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 2009;38:533-47
16. Rosethorne E, Turner RJ, Fairhurst RA, et al. Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists. Naunyn Schmiederbergs Arch Pharmacol 2010;382:255-63
17. Naline E, Trifilieff A, Fairhurst RA, et al. Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J 2007;29:575-81 (Pubitemid 46372108)
18. Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1- hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006;317:762-70
19. Sturton RG, Trifilief A, Nicholson AG, et al. Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 2008;324:270-5 (Pubitemid 350294169)
20. Duvauchelle T, Elharrar B, Knight H, et al. Single dose indacaterol, a novel 24-h 2 agonist, is well-tolerated in patients with mild asthma. Eur Respir J 2005;26:253s
21. Tarral A, Fauchaux N, Knight H, et al. Safety and tolerability of multiple-dose indacaterol, a novel 2-agonist, in patients with mild asthma. Eur Respir J 2005;26:253s
22. European Medicines Agency. Evaluation of Medicines for Human Use. Assessment Report EMA/659981/2009. Available from: http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/001114/ WC500053735.pdf#]
23. Beier J, Chanez P, Martinot JB, et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily 2-agonist, in patients with COPD: a 28-day randomised, placebo-controlled clinical trial. Pulm Pharmacol Ther 2007;20:740-9 (Pubitemid 47446351)
24. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008;102:1033-44
25. Bauwens O, Ninane V, Van de Maele B, et al. 24-h bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin 2009;25:463-70
26. Beier J, Beeh KM, Brookman L, et al. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009;22:492-6
27. Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010;23:165-71
28. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol vs twice-daily formoterol in COPD. Thorax 2010;65:473-9
29. Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150 mug once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010;10:11
30. Donohue JF, Fogarty C, Lotvall J, et al. Once daily bronchodilators for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:155-62
31. Vogelmeier C, Ramos Bourbon D. Jack, D, et al. Indacaterol provides 24-h bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res 2010;11:135
32. Magnussen H, Verkindre C, Jack D, et al. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med 2010;104:1869-76
33. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37:273-9
34. LaForce C, Aumann J, de Teresa Parreno L, et al. Sustained 24-h efficacy of once daily indacaterol (300 mcg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulm Pharmacol Ther 2011;24:162-8
35. Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a novel long-acting {beta}2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011;140:68-75
36. O'Donnell DE, Casaburi R, Vincken W, et al. Effect of indacaterol on exercise and lung hyperinflation in COPD. Respir Med 2011;105:1030-6
37. Beeh KM, Wagner F, Khindri S, et al. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 2011;8(5):340-5
38. Korn S, Kerwin E, Atis S, et al. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 2011;105:719-26
39. Balint B, Watz H, Amos C, et al. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis 2010;5:311-18
40. Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011;38:797-803
41. Khindri S, Sabo R, Harris S, et al. Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo-and positive-controlled, parallel-group thorough QT study. BMC Pulm Med 2011;11:31
42. Worth H, Chung KF, Felser JM, et al. Cardio-and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011;105:571-9
43. Donohue JF, Singh D, Kornmann O, et al. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 2011;6:477-92
44. Price D, Gray A, Gale R, et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med 2011;105(11):1635-47